{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:35:22Z","timestamp":1793968522583,"version":"4.8.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.biopha.2024.117577","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T01:40:16Z","timestamp":1729302016000},"page":"117577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Developing a novel P-glycoprotein inhibitor and pairing it with oral paclitaxel liposomes for enhanced cancer therapy"],"prefix":"10.1016","volume":"180","author":[{"given":"Sikai","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.117577_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2024.117577_bib2","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.3390\/cancers15225488","article-title":"The promise of piperine in cancer chemoprevention","volume":"15","author":"Benayad","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.117577_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121061","article-title":"Enhanced chemo-photodynamic therapy of an enzyme-responsive prodrug in bladder cancer patient-derived xenograft models","volume":"277","author":"Tan","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2024.117577_bib4","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1016\/j.apsb.2023.02.021","article-title":"Self-assembled nanoformulations of paclitaxel for enhanced cancer theranostics","volume":"13","author":"Pei","year":"2023","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.biopha.2024.117577_bib5","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.21.02050","article-title":"Randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and ifosfamide in patients with carcinosarcoma of the uterus or ovary: an NRG oncology trial","volume":"40","author":"Powell","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.117577_bib6","first-page":"131","article-title":"Overview of taxol safety","author":"Onetto","year":"1993","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"10.1016\/j.biopha.2024.117577_bib7","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.3390\/molecules25245986","article-title":"A compressive review about taxol\u00ae: history and future challenges","volume":"25","author":"Gallego-Jara","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2024.117577_bib8","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/annonc\/mdl104","article-title":"Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer","volume":"17","author":"Green","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2024.117577_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cac2.12225","volume":"42","author":"Zhang","year":"2022","journal-title":"Cancer Commun."},{"key":"10.1016\/j.biopha.2024.117577_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijrobp.2013.02.009","article-title":"Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer","volume":"86","author":"Werner","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.biopha.2024.117577_bib11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/10717544.2017.1279238","article-title":"pH-Responsive carriers for oral drug delivery: challenges and opportunities of current platforms","volume":"24","author":"Liu","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2024.117577_bib12","doi-asserted-by":"crossref","first-page":"S658","DOI":"10.1016\/j.annonc.2022.07.304","article-title":"265P Phase II study of DHP107 oral paclitaxel compared to IV paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer (MBC): Opera (NCT03326102)","volume":"33","author":"Rugo","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2024.117577_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211061989","article-title":"Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)","volume":"13","author":"Kim","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.biopha.2024.117577_bib14","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/17425247.2023.2231343","article-title":"Oral delivery of biomacromolecules by overcoming biological barriers in the gastrointestinal tract: an update","volume":"20","author":"Liu","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.biopha.2024.117577_bib15","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1021\/acsbiomaterials.2c00047","article-title":"Untangling mucosal drug delivery: engineering, designing, and testing nanoparticles to overcome the mucus barrier","volume":"8","author":"Watchorn","year":"2022","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.biopha.2024.117577_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114097","article-title":"Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers","volume":"182","author":"Haddadzadegan","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2024.117577_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/asj.13357","article-title":"Regulation of the intestinal barrier by nutrients: the role of tight junctions","volume":"91","author":"Suzuki","year":"2020","journal-title":"Anim. Sci. J."},{"key":"10.1016\/j.biopha.2024.117577_bib18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.tcb.2020.08.004","article-title":"Tight junction structure and function revisited","volume":"30","author":"Otani","year":"2020","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.biopha.2024.117577_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s40168-021-01137-3","article-title":"Gut microbiota regulation of P-glycoprotein in the intestinal epithelium in maintenance of homeostasis","volume":"9","author":"Foley","year":"2021","journal-title":"Microbiome"},{"key":"10.1016\/j.biopha.2024.117577_bib20","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1166\/jbn.2020.2956","article-title":"Enhancing oral bioavailability by paclitaxel polymeric micelles: role of transmembrane pathways in the oral absorption","volume":"16","author":"Liu","year":"2020","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.biopha.2024.117577_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114231","article-title":"Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel","volume":"233","author":"Shi","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2024.117577_bib22","first-page":"3379","article-title":"Coadministration of oral cyclosporin A enables oral therapy with paclitaxel","volume":"5","author":"Meerum Terwogt","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2024.117577_bib23","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1016\/j.apsb.2022.01.014","article-title":"Biological fate and interaction with cytochromes P450 of the nanocarrier material, d- \u03b1-tocopheryl polyethylene glycol 1000 succinate","volume":"12","author":"Ren","year":"2022","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.biopha.2024.117577_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114231","article-title":"Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel","volume":"233","author":"Shi","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2024.117577_bib25","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1021\/acs.jmedchem.0c01826","article-title":"Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor","volume":"64","author":"Smolinski","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2024.117577_bib26","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1248\/cpb.c22-00178","article-title":"Synthesis and evaluation of a paclitaxel-binding tripeptide micelle for lung cancer therapy","volume":"70","author":"Gao","year":"2022","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.biopha.2024.117577_bib27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1208\/s12249-022-02424-4","article-title":"Cell-penetrating peptides as passive permeation enhancers for transdermal drug delivery","volume":"23","author":"Chablani","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.biopha.2024.117577_bib28","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fphar.2020.00697","article-title":"Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application","volume":"11","author":"Xie","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2024.117577_bib29","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1039\/C9BM00274J","article-title":"Cell-penetrating peptide together with PEG-modified mesostructured silica nanoparticles promotes mucous permeation and oral delivery of therapeutic proteins and peptides","volume":"7","author":"Tan","year":"2019","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.biopha.2024.117577_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114044","article-title":"Cell-penetrating peptides in protein mimicry and cancer therapeutics","volume":"180","author":"Zorko","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2024.117577_bib31","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.3390\/ijms21051856","article-title":"Cell-penetrating peptide modified PEG-PLA micelles for efficient PTX delivery","volume":"21","author":"Shuai","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117577_bib32","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1016\/j.apsb.2023.05.029","article-title":"Versatile flexible micelles integrating mucosal penetration and intestinal targeting for effectively oral delivery of paclitaxel","volume":"13","author":"Liu","year":"2023","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.biopha.2024.117577_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13318-020-00651-3","article-title":"The effect of verapamil, a P-gpinhibitor, on the pharmacokinetics, safety, and tolerability of omadacycline in healthy adults: a phase I, open-label, single-sequence study","volume":"46","author":"Hunt","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.biopha.2024.117577_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112379","article-title":"Cinnamophilin overcomes cancer multi-drug resistance via allosterically modulating human P-glycoprotein on both drug binding sites and ATPase binding sites","volume":"144","author":"Teng","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2024.117577_bib35","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.bbamem.2016.04.014","article-title":"Lipid rafts-mediated endocytosis and physiology-based cell membrane traffic models of doxorubicin liposomes","volume":"1858","author":"Li","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2024.117577_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104989","article-title":"Jatrophane diterpenoids as multidrug resistance modulators from Euphorbia sororia","volume":"112","author":"Yang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.biopha.2024.117577_bib37","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11095-009-0026-9","article-title":"Model analysis of the concentration-dependent permeability of P-gp substrates","volume":"27","author":"Tachibana","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2024.117577_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120148","article-title":"Oral mucus-penetrating PEGylated liposomes to improve drug absorption: differences in the interaction mechanisms of a mucoadhesive liposome","volume":"593","author":"Yamazoe","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2024.117577_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123970","article-title":"Co-delivery of siBcl-2 and PTX with mitochondria-targeted functions to overcoming multidrug resistance","volume":"654","author":"Zhang","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2024.117577_bib40","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1021\/mp500439c","article-title":"Mechanisms of nanoparticle internalization and transport across an intestinal epithelial cell model: effect of size and surface charge","volume":"11","author":"Bannunah","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2024.117577_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2013.04.020","article-title":"Oral delivery of anticancer drugs: challenges and opportunities","volume":"170","author":"Thanki","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2024.117577_bib42","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1080\/15548627.2021.2016233","article-title":"AP2M1 mediates autophagy-induced CLDN2 (claudin 2) degradation through endocytosis and interaction with LC3 and reduces intestinal epithelial tight junction permeability","volume":"18","author":"Ganapathy","year":"2022","journal-title":"Autophagy"},{"key":"10.1016\/j.biopha.2024.117577_bib43","doi-asserted-by":"crossref","first-page":"R619","DOI":"10.1016\/j.cub.2021.01.036","article-title":"The cytoskeleton in phagocytosis and micropinocytosis","volume":"31","author":"Mylvaganam","year":"2021","journal-title":"Curr. Biol."},{"key":"10.1016\/j.biopha.2024.117577_bib44","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3945\/an.114.008052","article-title":"Genistein and cancer: current status, challenges, and future directions","volume":"6","author":"Spagnuolo","year":"2015","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.biopha.2024.117577_bib45","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/17425247.2021.1854222","article-title":"Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung","volume":"18","author":"Chen","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.biopha.2024.117577_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.856962","article-title":"Mucus and mucins: The underappreciated host defence system","volume":"12","author":"Sheng","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.biopha.2024.117577_bib47","article-title":"Understanding and targeting resistance mechanisms in cancer","volume":"4","author":"Lei","year":"2023","journal-title":"MedComm)"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222401463X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222401463X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:13:46Z","timestamp":1773969226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222401463X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":47,"alternative-id":["S075333222401463X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117577","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing a novel P-glycoprotein inhibitor and pairing it with oral paclitaxel liposomes for enhanced cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117577"}}